Vincerx Pharma, Inc. (VINC) Key Metrics
VINC valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $68,045
- Enterprise value
- −$4.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.46
VINC key metrics, 2019–2024
Fiscal year ended December 31, 2024 · U.S. dollarsVINC returns How much profit the business earns on the capital it uses.
VINC per-share figures Results divided by the shares outstanding at year-end.
VINC financial health Debt, liquidity and how easily interest is covered.
VINC efficiency & capital use Working capital cycle and where the cash goes.
VINC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VINC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VINC key metrics
2019–2024| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$5.75 | −$6.84 | −$11.27 | −$8.30 | −$7.53 | −$0.04 |
| Operating cash flow per share | −$4.99 | −$6.89 | −$10.28 | −$7.05 | −$1.60 | −$0.02 |
| Free cash flow per share | −$4.99 | −$6.89 | −$10.28 | −$8.16 | −$1.60 | −$0.02 |
| Cash per share | $0.95 | $2.18 | $9.05 | $23.53 | $43.39 | $0.48 |
| Book value per share | $0.52 | $1.91 | $8.22 | $21.18 | $17.82 | −$0.03 |
| Tangible book value per share | $0.52 | $1.91 | $8.22 | $21.18 | $17.82 | −$0.03 |
| Capex per share | $0.00 | $0.00 | $0.00 | $1.11 | $0.18 | $0.18 |
| Debt per share | — | $0.43 | $0.59 | $0.88 | — | — |
| Shares outstanding | 5.2M | 5.9M | 5.8M | 4.7M | 1.4M | 1.4M |
| Change in shares outstanding | −10.9% | +1.3% | +22.4% | +232.6% | −0.6% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −431.3% | −136.4% | −88.3% | −62.5% | −84.7% | — |
| Return on assets (ROA) | −229.4% | −103.6% | −73.9% | −43.5% | −34.0% | — |
| Return on tangible assets | −375.7% | −220.4% | −110.3% | −33.4% | −17.0% | — |
| Financial health | ||||||
| Total debt | — | $2.5M | $3.4M | $4.2M | — | — |
| Cash & short-term investments | $5.0M | $12.8M | $52.5M | $111.5M | $61.8M | $684,708 |
| Net debt | −$5.0M | −$10.3M | −$49.0M | −$107.3M | −$61.8M | −$684,708 |
| Debt / equity | — | 0.22 | 0.07 | 0.04 | — | — |
| Debt / assets | — | 0.14 | 0.06 | 0.04 | — | — |
| Net debt / EBITDA | — | — | — | — | — | −76.08 |
| Current ratio | 1.21 | 2.63 | 6.11 | 8.04 | 1.67 | 17.98 |
| Quick ratio | 1.21 | 2.63 | 6.25 | 8.04 | 1.67 | 17.98 |
| Interest coverage | — | — | -8.4 | -2.7 | — | — |
| Working capital | $1.1M | $9.1M | $46.8M | $97.9M | $25.3M | $747,041 |
| Invested capital | −$2.3M | $942,000 | −$1.4M | −$7.0M | −$36.4M | −$728,708 |
| Tangible asset value | $2.7M | $11.2M | $47.7M | $100.3M | $57.7M | −$43,000 |
| Net current asset value | $1.1M | $7.7M | $44.3M | $94.5M | $57.6M | $747,041 |
| Graham net-net per share | $0.09 | $1.12 | $7.11 | $19.87 | $39.52 | $0.45 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | — | — | $0 | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 15.46 | 12.90 | 4.78 |
| Efficiency | ||||||
| Days of inventory on hand | — | — | -481.2 | — | — | — |
| Days payables outstanding | 757.8 | 1,308.8 | 1,182.5 | 1,347.3 | 554.9 | 73.8 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — | — | — |
| Payables turnover | 0.48 | 0.28 | 0.31 | 0.27 | 0.66 | 4.94 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.0M | $1.2M | $1.4M | — | — | — |
| Average payables | $2.3M | $3.3M | $3.0M | $1.3M | $263,000 | $35,000 |
| Average inventory | — | — | −$1.2M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VINC's annual financial statements (latest annual report filed March 27, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VINC valuation and financial ratios
Vincerx Pharma earned a return on equity of −431.3% in fiscal 2024. The share count rose 265.3% from 1.4M to 5.2M over 5 years.
See the VINC income statement, the VINC chart for price history, or the VINC stock overview for the latest quote and news.
VINC key metrics FAQ
What is Vincerx Pharma's return on equity?
Vincerx Pharma's return on equity (ROE) was −431.3% in fiscal 2024: net income of -$30.1 million on average shareholders' equity of $7.0 million.
What is Vincerx Pharma's current ratio?
Vincerx Pharma's current ratio was 1.21 at the end of fiscal 2024: current assets were 1.21 times current liabilities.